99 related articles for article (PubMed ID: 23014186)
1. Targeting the human epidermal growth factor receptor 2 pathway in breast cancer.
Damodaran S; Olson EM
Hosp Pract (1995); 2012 Oct; 40(4):7-15. PubMed ID: 23299030
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.
Eroglu Z; Tagawa T; Somlo G
Oncologist; 2014 Feb; 19(2):135-50. PubMed ID: 24436312
[TBL] [Abstract][Full Text] [Related]
3. New approaches for human epidermal growth factor receptor 2-low and human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.
Britten K; McAndrew N
Curr Opin Obstet Gynecol; 2024 Feb; 36(1):34-39. PubMed ID: 38170550
[TBL] [Abstract][Full Text] [Related]
4. Emerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancer.
Chien AJ; Rugo HS
Breast Cancer Res Treat; 2013 Jan; 137(1):1-12. PubMed ID: 23143215
[TBL] [Abstract][Full Text] [Related]
5. Editorial for "Potential Antihuman Epidermal Growth Factor Receptor 2 Target Therapy Beneficiaries: The Role of MRI-Based Radiomics in Distinguishing Human Epidermal Growth Factor Receptor 2-Low Status of Breast Cancer".
Geitung JT
J Magn Reson Imaging; 2023 Nov; 58(5):1615-1616. PubMed ID: 36744580
[No Abstract] [Full Text] [Related]
6. Real-world impact of dual anti-HER2 antibodies on cardiac function in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.
Bao KK; Chan JC; Chan JG; Sutanto L; Cheung KM; Yiu HH
Breast; 2024 Feb; 73():103612. PubMed ID: 38007881
[TBL] [Abstract][Full Text] [Related]
7. Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer.
Alvarez RH; Hortobagyi GN
Breast Cancer; 2013 Apr; 20(2):103-10. PubMed ID: 23377763
[TBL] [Abstract][Full Text] [Related]
8. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.
Liu Y; Xu J; Choi HH; Han C; Fang Y; Li Y; Van der Jeught K; Xu H; Zhang L; Frieden M; Wang L; Eyvani H; Sun Y; Zhao G; Zhang Y; Liu S; Wan J; Huang C; Ji G; Lu X; He X; Zhang X
Nat Commun; 2018 Nov; 9(1):4718. PubMed ID: 30413718
[TBL] [Abstract][Full Text] [Related]
9. Does dual HER-2 blockade treatment increase the risk of severe toxicities of special interests in breast cancer patients: A meta-analysis of randomized controlled trials.
Hao S; Tian W; Gao B; Jiang Y; Zhang X; Zhang S; Guo L; Zhao J; Zhang G; Hu C; Yan J; Luo D
Oncotarget; 2017 Mar; 8(12):19923-19933. PubMed ID: 28199966
[TBL] [Abstract][Full Text] [Related]
10. New generation of breast cancer clinical trials implementing molecular profiling.
Zardavas D; Piccart-Gebhart M
Cancer Biol Med; 2016 Jun; 13(2):226-35. PubMed ID: 27458530
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
O'Sullivan CC; Bradbury I; Campbell C; Spielmann M; Perez EA; Joensuu H; Costantino JP; Delaloge S; Rastogi P; Zardavas D; Ballman KV; Holmes E; de Azambuja E; Piccart-Gebhart M; Zujewski JA; Gelber RD
J Clin Oncol; 2015 Aug; 33(24):2600-8. PubMed ID: 26101239
[TBL] [Abstract][Full Text] [Related]
12. Management of locally advanced breast cancer-perspectives and future directions.
Tryfonidis K; Senkus E; Cardoso MJ; Cardoso F
Nat Rev Clin Oncol; 2015 Mar; 12(3):147-62. PubMed ID: 25668732
[TBL] [Abstract][Full Text] [Related]
13. Complete pathologic response of HER2-positive breast cancer liver metastasis with dual anti-HER2 antagonism.
Schoellhammer HF; Hsu F; Vito C; Chu P; Park J; Waisman J; Kim J
BMC Cancer; 2014 Apr; 14():242. PubMed ID: 24708527
[TBL] [Abstract][Full Text] [Related]
14. Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer.
Zardavas D; Bozovic-Spasojevic I; de Azambuja E
Curr Opin Oncol; 2012 Nov; 24(6):612-22. PubMed ID: 23014186
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
16. Dual HER2 blockade: preclinical and clinical data.
Patel TA; Dave B; Rodriguez AA; Chang JC; Perez EA; Colon-Otero G
Breast Cancer Res; 2014 Aug; 16(4):419. PubMed ID: 25928889
[TBL] [Abstract][Full Text] [Related]
17. Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial.
Robidoux A; Tang G; Rastogi P; Geyer CE; Azar CA; Atkins JN; Fehrenbacher L; Bear HD; Baez-Diaz L; Sarwar S; Margolese RG; Farrar WB; Brufsky AM; Shibata HR; Bandos H; Paik S; Costantino JP; Swain SM; Mamounas EP; Wolmark N
Lancet Oncol; 2013 Nov; 14(12):1183-92. PubMed ID: 24095300
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
